TGFβ Controls Ovarian Cancer Cell Proliferation

There have been no major improvements in the overall survival of ovarian cancer patients in recent decades. Even though more accurate surgery and more effective treatments are available, the mortality rate remains high. Given the differences in origin and the heterogeneity of these tumors, research...

Full description

Saved in:
Bibliographic Details
Published in:International journal of molecular sciences 2017-07, Vol.18 (8), p.1658
Main Authors: Alsina-Sanchís, Elisenda, Figueras, Agnès, Lahiguera, Alvaro, Gil-Martín, Marta, Pardo, Beatriz, Piulats, Josep M, Martí, Lola, Ponce, Jordi, Matias-Guiu, Xavier, Vidal, August, Villanueva, Alberto, Viñals, Francesc
Format: Article
Language:English
Subjects:
Animals
Cell growth
Cell Proliferation
Càncer d'ovari
Disruption
Factors de creixement
Female
Growth factors
Homeostasis
Humans
IGF1R
Neoplasm Proteins - genetics
Neoplasm Proteins - metabolism
Ovarian cancer
Ovarian Neoplasms - genetics
Ovarian Neoplasms - metabolism
Ovarian Neoplasms - pathology
Proliferació cel·lular
proliferation
Review
Signal Transduction
TGFβ
Transforming growth factor
Transforming Growth Factor beta - genetics
Transforming Growth Factor beta - metabolism
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There have been no major improvements in the overall survival of ovarian cancer patients in recent decades. Even though more accurate surgery and more effective treatments are available, the mortality rate remains high. Given the differences in origin and the heterogeneity of these tumors, research to elucidate the signaling pathways involved is required. The Transforming Growth Factor (TGFβ) family controls different cellular responses in development and cell homeostasis. Disruption of TGFβ signaling has been implicated in many cancers, including ovarian cancer. This article considers the involvement of TGFβ in ovarian cancer progression, and reviews the various mechanisms that enable the TGFβ signaling pathway to control ovarian cancer cell proliferation. These mechanistic explanations support the therapeutic use of TGFβ inhibitors in ovarian cancer, which are currently in the early phases of development.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms18081658